Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
Sjoukje F. Oosting, Astrid A.M. van der Veldt, Rudolf S.N. Fehrmann, Corine H. GeurtsvanKessel, Rob van Binnendijk, Anne‐Marie C. Dingemans, Egbert F. Smit, T. Jeroen N. Hiltermann, Gerco den Hartog, Mathilda Jalving, Tatjana T Westphal, Arkajyoti Bhattacharya, Faye de Wilt, Annemarie Boerma, L. van Zijl, Guus F. Rimmelzwaan, Pia Kvistborg, Cécile A. C. M. van, Nynke Y. Rots, Debbie van Baarle, John B.A.G. Haanen, Elisabeth G.E. de Vries
Topics & Concepts
MedicineVaccinationImmunotherapyCancerInternal medicineImmunogenicityChemotherapyImmune systemOncologyImmunologySARS-CoV-2 and COVID-19 ResearchCOVID-19 and healthcare impactsCancer Immunotherapy and Biomarkers